🇺🇸 FDA
Patent

US 9125923

Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy

granted A61KA61K31/70A61K38/212

Quick answer

US patent 9125923 (Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy) held by The United States of America as represented by the Secretary of the Dept. of Health & Human Services expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Dept. of Health & Human Services
Grant date
Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/70, A61K38/212, A61P, A61P1/16